Past Events

The Controlling Cancer Summit 2016: 17th – 19th May 2016


 The annual Controlling Cancer Summit is an international academic event with plenty of opportunity for networking and debate.

 Agend    Abstract book

In an informal setting, this meeting will bring you up to date with current research and thinking regarding screening, prevention and treatment in this ever-growing field. Presenting at this event, we will have a variety of clinicians, academics and members of the pharmaceutical industry; we encourage presentations from the wide spectrum of cancer research, development and healthcare professionals.


  • The Deadline for abstract submissions for oral presentation is 10th February 2016
  • The early registration deadline is 20th March 2016
  • The Deadline for poster submission is 3rd May 2016

Who Should Attend:  This innovative and stimulating event is aimed at those working in research and development of drugs, industry partners, academia, biotechnology, diagnostic, clinicians and postgraduate students.



Event Listing

Talks Include

Dendritic cell derived exosomes for cancer therapyAssociate Professor Susanne GabrielssonKarolinska InstitutetSweden
New therapeutic approaches and repurposed drugs for targeting of glioma stem cells and treatment of glioblastomaProfessor Chaya BrodieHermelin Brain Tumor CenterUnited States
The antitumor activity of cannabinoids in colorectal cancerDr David MeiriTechnion-Israel Institute of TechnologyIsrael
The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasisDr. Alice CarrierCancer Research Center of Marseille (CRCM)France
NQO1, GSTM1, and GSTT1 genetic polymorphisms and the risk of developing cancer among FilipinosDr Pia Marie AlbanoResearch Center for the Natural and Applied SciencesPhilippines
DNA damage repair and p53 gene in platinum-drug resistanceDr Jing Jie YuMary Babb Randolph Cancer CenterUnited States
Using chemical and biological data for targeted compound selection and biomarker discovery in cancer and beyond
Dr Andreas BenderUniversity of CambridgeUnited Kingdom
DNA repair gene polymorphisms as risk factors and chemotherapy response predictors for lung adenocarcinoma in SerbiaIvana BoljevicLaboratory for Molecular Genetics,Institute for Oncology and Radiology of SerbiaSerbia
CYP3A variation, hormone levels, breast cancer risk and prognosisDr Olivia FletcherGenetic Epidemiology The Institute of Cancer ResearchUnited Kingdom
Omics biomarkers and their implication in cancer controlDr Mukesh VermaNational Institutes of Health (NIH)United States
p53 regulates miRNA-AGO2 association to control miRNA-mediated post-transcriptional gene repression in cancerDr Leandro CastellanoImperial College LondonUnited Kingdom
Targeting non death domain-containing TNFR family members for cancer therapy: direct, carcinoma cell-specific death by CD40 signallingDr Nikolaos GeorgopoulosUniversity of HuddersfieldUnited Kingdom
Non-Natural Nucleosides as Therapeutic Agents Against GlioblastomaDr Anthony J. BerdisCleveland State UniversityUnited States
Nucleosomics®- Revolutionising Cancer DiagnosticsDr Mark EcclestonVolitionRxUnited Kingdom
Cancer resistance to photodynamic therapyDr. Marek MuriasPoznan University of Medical SciencesPoland
IV Iron in Anemia of Oncology, Inflammation, and other disorders of Iron deficiencyDr David HenryUniversity of PennsylvaniaUnited States
DNA methylation in epithelial-to-mesenchymal transitionDr Bozena SmolkovaSlovak Academy of SciencesSlovakia
Adoptive T cell Therapy for CancerDr David Edward GilhamThe University of ManchesterUnited Kingdom
Crosstalk between cell death modalities as anticancer targetDr Marc DiederichSeoul National UniversityKorea
Targeted nanomedicines in cancer therapyDr Christine DufesUniversity of Strathclyde

United Kingdom
Signalling therapy for cancer: from target proteins to target signalling networks Dr Alexey GoltsovUniversity of Abertay DundeeUnited Kingdom
Stem Cell based Therapies for Cancer: Mechanism and Translation into ClinicsDr. Khalid ShahHarvard Medical SchoolUnited States
DNA methylation in early detection and risk prediction of women specific cancersProfessor Martin WidschwendterInstitute for Women´s HealthUnited Kingdom
Cognitive impairment in patients with glioblastoma: single institution experienceDr. Ana Misir KrpanUniversity Hospital Center ZagrebCroatia
Precious metals for cancer treatment - a novel approach
Isolda RomeroUniversity of WarwickUnited Kingdom
Molecular factors associated with resistance to drugs targeting BRAF in malignant melanomaDr Suzanne Egyházi BrageDepartment of Oncology-PathologySweden
Responsive lanthanide complexes for imaging of key cell cycle regulators and inhibition of tumor cellsDr. Gary Ka-Leung WongHong Kong Baptist UniversityHong Kong
Immunotherapy for cancer dormancyDr. Masoud H. ManjiliVCU School of MedicineUnited States
RAD18 is involved in the resistance of glioblastoma cancer stem cells to the therapy.Dr Chames KermiGenome Surveillance and Stability Laboratory, Institute of Human Genetics (IGH)France
Recognition of LINE-1 derived DNA by the cGAS-STING pathway leads to inflammation in Fanconi AnemiaDr. Jessica GuerraCNRSMontpellier, France
Adoptive T cell Therapy for Cancer Dr.Gray KueberuwaUniversity of ManchesterUnited Kingdom
TBCDr Kenneth J. HsuKenneth Hsu Center of Cancer StudiesUnited Kingdom

Advisory Board Members

Dr Hendrik-Tobias ArkenauSarah Cannon Research Institute UKUnited Kingdom
Professor Rui Amaral Mendes
Case Western Reserve University
United States
Professor Anthony Miller
University of Toronto
Dr Alenka FokterCelje General HospitalSlovenia
Dr. Xiaoyan JiangBC Cancer Agency and University of British ColumbiaCanada
Professor Shimon SlavinThe International Center for Cell Therapy & Cancer Immunotherapy (CTCI)Israel

The Controlling Cancer Summit 2016 has an open abstract session:  Abstracts can be submitted on any subject related to cancer

CPD Credits

Related Past Agendas



Email:? enquiries [@]

Phone:?(+44) 020 3807 3712

Abstract and Poster Presentations

All abstracts accepted for oral presentation are also automatically accepted for poster presentation


Cancellation Policy

Join the conversation

Related past events




This is a closed event

Only participants who have registered are licensed to attend this event. This is for the protection and peace of mind of our speakers who are presenting unpublished work. We ask our participants not to share their screen with people who are not registered for the event and will fine those who do.

Latest Euroscicon Tweets

Error: You currently have access to a subset of Twitter API v2 endpoints and limited v1.1 endpoints (e.g. media post, oauth) only. If you need access to this endpoint, you may need a different access level. You can learn more here: